In the first broad genetic landscape mapped of a Burkitt lymphoma tumour, scientists at Duke Medicine and their collaborators identified 70 mutations, including several that had not previously been associated with cancer and a new one that was unique to the disease.
Findings from the genetic sequencing of Burkitt lymphoma, an aggressive form of lymphoma, could be used to develop new drugs or aim existing therapies at mutations known to be susceptible
‘This study lays out the most common genetic alterations in the disease, and allows us to understand the biology of the disease so we can design better therapies,’ said Sandeep S. Dave, M.D., MBA, MS, associate professor at Duke and senior author of the study.
Dave and colleagues sequenced the first complete Burkitt lymphoma genome, plus the genes from 59 additional Burkitt cases and 94 diffuse large B cell lymphomas, which share many of the same characteristics of Burkitt lymphoma. Similarities between the malignancies can often lead to mistaken diagnoses and failed treatments.
The researchers reported striking differences in the gene mutation patterns of Burkitt lymphomas vs. the diffuse large B cell lymphomas.
‘It’s important that doctors make the right diagnosis for Burkitt lymphoma, which can be cured with the correct therapies,’ Dave said. ‘But if misdiagnosed and given the standard chemotherapy regimes for diffuse large B cell lymphomas, Burkitt lymphoma patients invariably relapse.’
The analysis identified 70 genes that were frequently mutated in the Burkitt lymphomas, including a number of genes that were identified in cancer for the first time. One of the newly identified gene mutations, ID3, appeared in 34 percent of the Burkitt cases, but was not evident in any of the diffuse large B cell lymphomas.
The mutation has a silencing effect on a gene that suppresses cell growth, enabling cells to multiply. Dave said this alteration alone may not cause cancer, but when it occurs along with the MYC gene mutations that are common in Burkitt lymphoma and other malignancies, it works like an accelerant to fuel tumour growth.
That finding could prove helpful for developing a new drug to function like a normal ID3 gene and suppress cancer cell proliferation in lymphomas as well as numerous other cancers.
‘If we can find a way to mimic ID3, restoring the function of the gene to slow the growth of tumours, this could provide a new treatment approach,’ Dave said. ‘We have experiments that suggest this is the case, but much more research is needed. This work provides a starting point.’ Duke Medicine